Story perspectives

Stryker to Acquire Inari Medical for $4.9 Billion

1/7/2025

47 5

Summary

Story summary

Stryker Corporation will acquire Inari Medical for about $4.9 billion, paying $80 per share in cash.
This acquisition strengthens Stryker's offerings in venous disease treatments, especially venous thromboembolism.
The transaction is set to close by Q1 2025, subject to regulatory approvals.
Both boards have unanimously approved the deal, which includes a $163 million termination fee for Inari.
Inari Medical experienced a 22% revenue growth in 2024, despite reporting a net loss.

History

Historical Context

Stryker Corporation's $4.9 billion acquisition of Inari Medical mirrors past healthcare mergers aimed at expanding treatment capabilities. Similar to Stryker's 2013 purchase of MAKO Surgical, this deal reinforces strategic growth in specialized medical technologies, reflecting a trend where companies consolidate to enhance their market presence in niche medical fields.

1 of 2

Story summary

Stryker Corporation will acquire Inari Medical for about $4.9 billion, paying $80 per share in cash.
This acquisition strengthens Stryker's offerings in venous disease treatments, especially venous thromboembolism.
The transaction is set to close by Q1 2025, subject to regulatory approvals.
Both boards have unanimously approved the deal, which includes a $163 million termination fee for Inari.
Inari Medical experienced a 22% revenue growth in 2024, despite reporting a net loss.

1 / 2